Substanzen

2C-B-FLY is a psychedelic compound that primarily acts as a partial agonist at serotonin receptors, particularly the 5-HT2A receptor, which is implicated in its hallucinogenic effects. Additionally, it may influence other serotonin receptor subtypes and modulate the release of neurotransmitters such as dopamine and norepinephrine, contributing to its psychoactive properties. Its effects are thought to arise from alterations in serotonergic signaling and neural connectivity within the brain.

DOC acts primarily as a partial agonist at the 5-HT2A receptor, inducing psychedelic effects. It also agonizes TAAR1, contributing to its stimulant properties. Additionally, DOC engages α1-adrenoceptors, causing vasoconstriction, and affects 5-HT2B and 5-HT2C receptors.

2C-C, a member of the 2C family of phenethylamines, primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A and 5-HT2C receptors. Its action on these receptors is associated with alterations in mood, perception, and cognition, as well as potential effects on the dopaminergic and noradrenergic systems. Additionally, 2C-C may influence the release of neurotransmitters such as serotonin and dopamine, contributing to its psychoactive effects.

DOM acts primarily as a partial agonist at the 5-HT2A receptor, inducing its psychedelic effects. It also partially agonizes 5-HT2B receptors, posing cardiac risks with chronic use. TAAR1 agonism contributes to its stimulant properties, enhancing neurotransmitter release.

2C-D acts primarily as a partial agonist at the 5-HT2A receptor, which is responsible for its psychedelic effects. It also interacts with 5-HT2C and 5-HT1A receptors, modulating serotonergic neurotransmission and influencing perception and mood.

2C-E primarily acts as a partial agonist at the 5-HT2A receptor, which is responsible for its psychedelic effects. It also interacts with 5-HT2C and 5-HT1A receptors, modulating serotonergic transmission and contributing to its complex sensory and emotional effects.

DOI acts as a partial agonist at the 5-HT2A receptor, inducing psychedelic effects. It also partially agonizes the 5-HT2B receptor, affecting cardiovascular function, and acts as a TAAR1 agonist, contributing to its stimulant properties.

2C-I acts primarily as a partial agonist at the 5-HT2A receptor, which is responsible for its psychedelic effects. It also has activity at 5-HT2C and 5-HT1A receptors, contributing to its complex sensory and emotional effects.

2C-P acts as a potent agonist at the 5-HT2A and 5-HT2C serotonin receptors, leading to intense psychedelic effects. Its high potency and long duration are due to strong receptor binding, making it more dangerous than other 2C-x compounds.

2C-T-2 is a psychedelic compound that primarily acts as a partial agonist at serotonin 5-HT2A and 5-HT2C receptors, which are implicated in the modulation of mood, perception, and cognition. Additionally, it may influence the dopaminergic system by interacting with dopamine receptors, contributing to its psychoactive effects. Its action on these neurotransmitter systems is thought to underlie its hallucinogenic properties.

2C-T-7 is a psychedelic compound that primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its hallucinogenic effects. It may also interact with other serotonin receptors, such as 5-HT2C, and has been shown to influence the release of neurotransmitters like dopamine and norepinephrine, contributing to its psychoactive properties. Additionally, it may affect the reuptake of serotonin, further modulating serotonergic signaling.

3-Fluoromethamphetamine acts as a reuptake inhibitor for dopamine and serotonin transporters (DAT and SERT), increasing synaptic levels of these neurotransmitters. This leads to stimulant and euphoric effects. It also has minor activity at norepinephrine transporters (NET).

3-MMC acts as a monoamine releasing agent by reversing transport at SERT, NET, and DAT. It primarily targets SERT, enhancing serotonin release, with secondary effects on norepinephrine and dopamine via NET and DAT, respectively, contributing to its stimulant and empathogenic effects.

4-Chloromethcathinone (4-CMC) primarily acts as a stimulant by inhibiting the reuptake of monoamine neurotransmitters, particularly dopamine, norepinephrine, and serotonin, thereby increasing their levels in the synaptic cleft. It is thought to interact with the dopamine transporter (DAT) and the norepinephrine transporter (NET), leading to enhanced dopaminergic and noradrenergic signaling, which contributes to its stimulant effects. Additionally, 4-CMC may have some affinity for serotonin receptors, although its primary action is on the monoamine transporters.

4-Fluoroamphetamine acts as a monoamine releasing agent, reversing transport at DAT, NET, and SERT, with a stronger serotonergic effect due to fluorine substitution. This results in increased release of serotonin, dopamine, and norepinephrine, contributing to its stimulant-empathogenic profile.

4-Fluoromethamphetamine primarily acts as a reuptake inhibitor of dopamine and serotonin by interacting with DAT and SERT, leading to increased synaptic concentrations of these neurotransmitters. It also has minor releasing effects on norepinephrine via NET.

4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine) primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its psychedelic effects. It may also interact with other serotonin receptors, such as 5-HT1A and 5-HT2C, influencing neurotransmitter systems related to mood, perception, and cognition. Additionally, its effects may involve modulation of dopaminergic and noradrenergic systems, contributing to its overall psychoactive profile.

4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine) primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its psychedelic effects. Additionally, it may influence the dopaminergic and noradrenergic systems, potentially affecting dopamine and norepinephrine release through interactions with their respective transporters. This multi-target action contributes to its complex pharmacological profile.

4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-isopropyltryptamine) primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its psychedelic effects. It may also interact with other serotonin receptors and potentially influence dopamine and norepinephrine systems, contributing to its overall psychoactive profile. Additionally, its structural similarity to other tryptamines suggests it may affect monoamine transporters, although specific interactions require further investigation.

5-APB (5-(2-aminopropyl)benzofuran) primarily acts as a releasing agent for monoamine neurotransmitters, particularly serotonin, dopamine, and norepinephrine. It is thought to interact with the serotonin transporter (SERT) and the dopamine transporter (DAT), leading to increased synaptic levels of these neurotransmitters. Additionally, 5-APB may also exhibit partial agonist activity at certain serotonin receptors, particularly the 5-HT2A receptor.

5-MAPB primarily acts as a serotonin releasing agent by inhibiting the serotonin transporter (SERT), increasing serotonin levels in the synaptic cleft. It also functions as an agonist at 5-HT2A receptors, contributing to its empathogenic effects. Additionally, it affects dopamine and norepinephrine systems.

5-Methoxy-DiPT (5-MeO-DiPT) primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its psychedelic effects. It may also influence other serotonin receptors and transporters, potentially affecting the serotonergic system and leading to alterations in mood, perception, and cognition. Additionally, its interaction with other neurotransmitter systems, such as dopamine and norepinephrine, may contribute to its overall effects.

5-MeO-DMT acts as a potent agonist at 5-HT1A and 5-HT2A receptors, leading to its psychedelic effects. It also interacts with Sigma-1 receptors, modulating serotonergic and dopaminergic systems, contributing to its unique psychoactive profile.

5-Methoxy-MiPT is a tryptamine derivative that primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in its hallucinogenic effects. It may also interact with other serotonin receptors and potentially influence dopamine and norepinephrine systems, contributing to its psychoactive properties. The exact mechanisms and receptor interactions are still under investigation, and further research is needed to fully elucidate its pharmacodynamics.

6-APB (6-(2-aminopropyl)benzofuran) primarily acts as a releasing agent for monoamine neurotransmitters, particularly serotonin, dopamine, and norepinephrine. It is thought to interact with the serotonin transporter (SERT) and the dopamine transporter (DAT), leading to increased synaptic levels of these neurotransmitters. Additionally, 6-APB may also exhibit affinity for various serotonin receptor subtypes, contributing to its psychoactive effects.

Weitere Daten folgen

Weitere Daten folgen

7-Hydroxymitragynine acts as a potent agonist at the μ-opioid receptor (MOR), leading to analgesic and euphoric effects through inhibition of adenylyl cyclase and modulation of ion channels. It also shows activity at δ-opioid and κ-opioid receptors, contributing to its overall pharmacological profile.

Acetylfentanyl acts as a potent full agonist at the mu-opioid receptor (MOR), leading to analgesia, euphoria, and respiratory depression. It also has activity at delta and kappa opioid receptors, contributing to its overall pharmacological profile.

Adrafinil wird im Körper zu Modafinil metabolisiert, welches die Wiederaufnahme von Dopamin und Noradrenalin hemmt. Dies führt zu einer erhöhten Wachsamkeit und Konzentration.

Agomelatine is a melatonergic antidepressant that primarily acts as an agonist at melatonergic receptors MT1 and MT2, which are involved in regulating circadian rhythms and sleep-wake cycles. Additionally, it functions as an antagonist at serotonin 5-HT2C receptors, leading to increased release of norepinephrine and dopamine in the prefrontal cortex, thereby influencing mood and emotional regulation. This dual action contributes to its antidepressant effects while also promoting sleep.

Akuamma primarily acts as an agonist at mu-opioid receptors (MOR), leading to analgesic and sedative effects. It also exhibits activity at kappa-opioid receptors (KOR) and may interact with delta-opioid receptors, contributing to its overall pharmacological profile.

Al-LAD wirkt primär als Agonist am 5-HT2A-Rezeptor, was zu den charakteristischen psychedelischen Effekten führt. Die Substanz beeinflusst die serotonerge Transmission im Gehirn und kann visuelle sowie kognitive Veränderungen hervorrufen.

Alfentanil wirkt als Agonist am μ-Opioidrezeptor, was zu einer starken Schmerzlinderung führt. Es hat eine schnelle Wirkungseintritt und eine kurze Wirkdauer, was es besonders für die Anästhesie geeignet macht.

Allylescaline is a psychedelic compound that primarily acts as a serotonin receptor agonist, particularly at the 5-HT2A receptor, which is implicated in the modulation of mood, perception, and cognition. Additionally, it may influence the dopaminergic and glutamatergic systems, contributing to its psychoactive effects. Its interaction with these neurotransmitter systems is thought to underlie the altered states of consciousness associated with its use.

Alpha-GPC (L-alpha-glycerylphosphorylcholine) acts as a choline source that enhances acetylcholine synthesis, primarily by increasing choline availability in the brain. It is thought to facilitate cholinergic neurotransmission by promoting the release of acetylcholine at synapses, thereby influencing cognitive functions and memory. Additionally, Alpha-GPC may interact with various receptors, including muscarinic and nicotinic acetylcholine receptors, contributing to its neuroprotective and cognitive-enhancing effects.